M
Michael J. Krautkramer
Researcher at Avid Radiopharmaceuticals
Publications - 4
Citations - 1831
Michael J. Krautkramer is an academic researcher from Avid Radiopharmaceuticals. The author has contributed to research in topics: Florbetaben & Alzheimer's disease. The author has an hindex of 4, co-authored 4 publications receiving 1671 citations.
Papers
More filters
Journal ArticleDOI
Use of Florbetapir-PET for Imaging β-Amyloid Pathology
Christopher M. Clark,Julie A. Schneider,Barry J. Bedell,Thomas G. Beach,Warren B. Bilker,Mark A. Mintun,Michael J. Pontecorvo,Franz Hefti,Alan Carpenter,Matthew Flitter,Michael J. Krautkramer,Hank F. Kung,R. Edward Coleman,P. Murali Doraiswamy,Adam S. Fleisher,Marwan N. Sabbagh,Carl H. Sadowsky,Eric M. Reiman,Simone P. Zehntner,Daniel Skovronsky +19 more
TL;DR: Evidence is provided that a molecular imaging procedure can identify β-amyloid pathology in the brains of individuals during life and for the prediction of progression to dementia.
Journal ArticleDOI
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study
Christopher M. Clark,Michael J. Pontecorvo,Thomas G. Beach,Barry J. Bedell,R. Edward Coleman,P. Murali Doraiswamy,Adam S. Fleisher,Eric M. Reiman,Marwan N. Sabbagh,Carl H. Sadowsky,Julie A. Schneider,Anupa Arora,Alan Carpenter,Matthew Flitter,Abhinay D. Joshi,Michael J. Krautkramer,Ming Lu,Mark A. Mintun,Daniel Skovronsky +18 more
TL;DR: The results of this study validate the binary visual reading method approved in the USA for clinical use with flor betapir and suggest that florbetapir could be used to distinguish individuals with no or sparse amyloid plaques from those with moderate to frequent plaques.
Journal ArticleDOI
Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue.
Seok Rye Choi,Julie A. Schneider,David A. Bennett,Thomas G. Beach,Barry J. Bedell,Simone P. Zehntner,Michael J. Krautkramer,Hank F. Kung,Daniel Skovronsky,Franz Hefti,Christopher M. Clark +10 more
TL;DR: The results support the use of florbetapir F 18 as an amyloid positron emission tomography ligand to identify the presence of Alzheimer disease pathology in patients with signs and symptoms of progressive late-life cognitive impairment.
Journal ArticleDOI
Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline.
Michael Grundman,Michael J. Pontecorvo,Stephen Salloway,P. M. Doraiswamy,Adam S. Fleisher,Carl H. Sadowsky,Anil K. Nair,Andrew Siderowf,Ming Lu,Anupa Arora,Agbulos A,Matthew Flitter,Michael J. Krautkramer,Sarsour K,Daniel Skovronsky,Mark A. Mintun +15 more
TL;DR: In summary, amyloid imaging results altered physician’s diagnostic thinking, intended testing, and management of patients undergoing evaluation for cognitive decline.